News and Trends 4 Nov 2019 Finnish Genetics Study Provides Clues for Treating Type 2 Diabetes A genetic mutation common to Finnish populations has been found to protect against type 2 diabetes by increasing insulin in the blood, providing a potential target for new drugs. The mutation is found in at least 0.2% of the population in western Finland, whereas it only appears in 0.02% of other European populations. The mutation […] November 4, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 30 Sep 2019 Update: Mixed Results for Adocia as Legal Fight with Eli Lilly Comes to a Close Update (30/09/2019): A long legal battle between Adocia and Eli Lilly over a fast-acting insulin treatment development deal has finished with mixed results for Adocia. Eli Lilly has now paid €13M to Adocia, after the US Arbitration Association Panel supported Adocia’s claim last year. The payment consists of a milestone payment of €10.1M plus interest. […] September 30, 2019 - 4 minutesmins - By Editorial Team Share WhatsApp Twitter Linkedin Email
News and Trends 23 Sep 2019 FDA Greenlights First Oral Version of Novo Nordisk’s Type 2 Diabetes Drug The first oral drug for type 2 diabetes belonging to the class of GLP-1 agonists, developed by Novo Nordisk, has got the go-ahead from the FDA. The Danish company is known for its blockbuster injectable drug in the same class — liraglutide — that is now one of the most highly prescribed drugs in the […] September 23, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 2 Sep 2019 How the DIY Diabetes Community Made the Artificial Pancreas Possible Six years ago, his three-year-old daughter was diagnosed with type 1 diabetes. This led Milos Kozak, a software developer from Prague, to join the DIY diabetes community. “After the diagnosis, I started to look for some solutions because I was really disappointed by the technology available on the market for diabetes,” Kozak told me. That’s […] September 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Aug 2019 Type 1 Diabetes Immunotherapy Shows Promise in Phase I An immunotherapy designed by the Belgian biotech Imcyse to prevent type 1 diabetes has shown signs of clinical benefits and no major safety issues in a phase I trial. The phase I trial recruited 41 patients newly diagnosed with type 1 diabetes. Imcyse injected the patients with different doses of its treatment and monitored the […] August 28, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jul 2019 French Biotech’s Plant Extract Cuts Blood Glucose in Prediabetic People A plant extract developed by the French biotech Valbiotis is the first food supplement to reduce blood glucose levels in people at high risk of developing type 2 diabetes. In a phase IIa trial, Valbiotis compared its food supplement with a placebo in 51 people with prediabetes. After six months, the supplement had reduced blood […] July 5, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 2 Jul 2019 Microbiome Food Supplement Improves Metabolic Syndrome in Overweight People A food supplement made from bacteria, developed by a Belgian research group, has improved symptoms of the metabolic syndrome including insulin resistance and high blood cholesterol levels in overweight volunteers at risk of heart disease and type 2 diabetes. The metabolic syndrome is a collection of conditions including high blood cholesterol, insulin resistance and high […] July 2, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jun 2019 Belgian Biotech’s €35M Series B to Fund Potential Type 1 Diabetes Cure The Belgian company Imcyse has raised €35M in a Series B round to develop a potential cure for chronic autoimmune conditions including type 1 diabetes and multiple sclerosis. Imcyse will use the money to fund phase II trials of a peptide-based treatment for type 1 diabetes. The funds will also help the company to launch […] June 18, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Startup Scout 7 Jun 2019 This Biotech Transplants Cells into the Eye to Personalize Diabetes Treatments Up north in Stockholm, the Swedish company Biocrine aims to personalize diabetes treatments by screening drugs in pancreatic cells that have been transplanted into the eye. Mission: To test new drugs for type 1 and type 2 diabetes on pancreatic cells transplanted into the eye, where the cells can thrive and be easily monitored with […] June 7, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 9 Apr 2019 French First-in-Class Diabetes Drug Nails Phase III Trial An oral first-in-class drug targeting the mitochondria, developed by the French biotech Poxel, has shown big potential for treating type 2 diabetes in a phase III trial in Japan. Poxel’s lead candidate drug imeglimin has taken a step closer to entering the huge market for diabetes type 2 treatments. In a phase III trial in […] April 9, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 29 Mar 2019 French Diabetes Company Cellnovo Goes into Administration Paris-based Cellnovo has cut down on staff as well as stopped manufacturing and selling its diabetes management system as the company found itself unable to scale up. Until this week, Cellnovo was selling a diabetes management system consisting of a small insulin pump that was controlled via smartphone. Hundreds of diabetics using this technology have […] March 29, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
In Depth 11 Mar 2019 The Three Steps Needed to Fully Automate the Artificial Pancreas New advances in diabetes research are making it possible to develop a fully automated insulin delivery system that can control blood sugar without any input from the patient. This so-called artificial pancreas could be here within the next decade, but there are still three main challenges that scientists have to address to get us there. […] March 11, 2019 - 11 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email